Trials / Completed
CompletedNCT00689104
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,336 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | Tablets |
| DRUG | Tolterodine | Capsules |
| DRUG | Placebo to Mirabegron | Matching mirabegron placebo tablets. |
| DRUG | Placebo to Tolterodine | Matching tolterodine placebo capsules. |
Timeline
- Start date
- 2008-04-28
- Primary completion
- 2009-03-24
- Completion
- 2009-03-24
- First posted
- 2008-06-03
- Last updated
- 2024-11-20
- Results posted
- 2012-10-17
Locations
218 sites across 30 countries: Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00689104. Inclusion in this directory is not an endorsement.